Varaico: Literature-Extracted Genetic Variants

Gene:NFE2L2
Variant:p.R34Q
Back to variants list

NFE2L2

NM_006164.5:p.R34Q

Associated Papers

The complexity of tobacco smoke-induced mutagenesis in head and neck cancer.

Torrens L et al.

Nature Genetics, 2025

40164736 (PubMed )
Supplement: 41588_2025_2134_MOESM4_ESM.xlsx › Supplementary_Table_15

Decoding the functional impact of the cancer genome through protein-protein interactions.

Fu H et al.

Nature Reviews. Cancer, 2025

Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: A retrospective cohort study.

Iwasaki T et al.

Cancer Science, 2024

Hallmarks of a genomically distinct subclass of head and neck cancer.

Muijlwijk T et al.

Nature Communications, 2024

39428388 (PubMed )
Supplement: 41467_2024_53390_MOESM4_ESM.xlsx › 3._List_of_all_somatic_variants

GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.

Ikeuchi H et al.

Oncogene, 2024

39095584 (PubMed )
Supplement: 41388_2024_3105_MOESM2_ESM.xlsx › Supplementary_Table_S6

Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation.

Ueberroth BE et al.

Journal of Gastrointestinal Cancer, 2024

Arginines of the CGN codon family are Achilles' heels of cancer genes.

Trexler M et al.

Scientific Reports, 2024

Differential squamous cell fates elicited by NRF2 gain of function versus KEAP1 loss of function.

Takahashi J et al.

Cell Reports, 2024

Molecular characterization of the evolution of premalignant lesions in the upper aerodigestive tract.

Lechner A et al.

Frontiers in Oncology, 2024

38706595 (PubMed )
Supplement: Table_3.xlsx › Sheet1

Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1.

Wallen ZD et al.

Frontiers in Oncology, 2024

39664186 (PubMed )
Supplement: Table2.xlsx › Supplementary_Table_2

Nrf2, A Target for Precision Oncology in Cancer Prognosis and Treatment.

Ngo HKC et al.

Journal of Cancer Prevention, 2023

Mining cancer genomes for change-of-metabolic-function mutations.

Tu KJ et al.

Communications Biology, 2023

37950065 (PubMed )
Supplement: 42003_2023_5475_MOESM2_ESM.pdf

Multidirectional characterization of cellular composition and spatial architecture in human multiple primary lung cancers.

Wang Y et al.

Cell Death & Disease, 2023

37488117 (PubMed )
Supplement: 41419_2023_5992_MOESM3_ESM.xls › MPLC_P2-P31

Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors.

Kim M et al.

Cancer Research and Treatment, 2023

Utilization of cytologic cell blocks for targeted sequencing of solid tumors.

Vormittag-Nocito E et al.

Cancer Medicine, 2023

36125633 (PubMed )
Supplement: CAM4-12-4042-s001.xlsx › Sheet1

APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma.

Cannataro VL et al.

Lung Cancer (amsterdam, Netherlands), 2022

High expression of nuclear NRF2 combined with NFE2L2 alterations predicts poor prognosis in esophageal squamous cell carcinoma patients.

Jiang X et al.

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2022

Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.

Garcia-Prieto CA et al.

Bioinformatics (oxford, England), 2022

35512388 (PubMed )
Supplement: btac306_supplementary_data.zip › Supplementary_files.zip › Supplementary_files › Supplementary_file_8.xlsx › Sheet1

Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making.

Sun D et al.

Frontiers in Oncology, 2022

36425562 (PubMed )
Supplement: Table_5.xlsx › Sheet1

Profile of esophageal squamous cell carcinoma mutations in Brazilian patients.

Munari FF et al.

Scientific Reports, 2021

Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases.

Baschnagel AM et al.

Scientific Reports, 2021

33510214 (PubMed )
Supplement: 41598_2021_81832_MOESM1_ESM.pdf

Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer.

Scholl SM et al.

Ebiomedicine, 2020

33096476 (PubMed )
Supplement: mmc2.xlsx › RAIDS_algo_filtering_wLOH_forma

Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma.

Cui Y et al.

Cell Research, 2020

Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.

Shi MJ et al.

Genome Medicine, 2020

32988402 (PubMed )
Supplement: 13073_2020_781_MOESM2_ESM.xlsx › 112_Potenti_APO-associ_panCa

Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites.

Saigusa D et al.

Cancer Science, 2020

31828882 (PubMed )
Supplement: CAS-111-667-s002.xlsx › Table_S3

Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.

Torrente L et al.

Redox Biology, 2020

32007910 (PubMed )
Supplement: mmc2.xlsx › Table_1_LuSCC

Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes.

Dong X et al.

Communications Biology, 2020

31925297 (PubMed )
Supplement: 42003_2019_736_MOESM10_ESM.xlsx › Sheet1

The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.

Punta M et al.

Frontiers in Immunology, 2020

33133066 (PubMed )
Supplement: Table_1.xlsx › Drivers-not-HR

Analysis of error profiles in deep next-generation sequencing data.

Ma X et al.

Genome Biology, 2019

30867008 (PubMed )
Supplement: 13059_2019_1659_MOESM1_ESM.xlsx › S3_b

A catalogue of somatic NRF2 gain-of-function mutations in cancer.

Kerins MJ et al.

Scientific Reports, 2018

30150714 (PubMed )
Supplement: 41598_2018_31281_MOESM3_ESM.xlsx › table1lungmuts

Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC).

Frank R et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018

KEAP1/NRF2 signaling pathway mutations in cervical cancer.

Chu XY et al.

European Review for Medical and Pharmacological Sciences, 2018

Pan-urologic cancer genomic subtypes that transcend tissue of origin.

Chen F et al.

Nature Communications, 2017

28775315 (PubMed )
Supplement: 41467_2017_289_MOESM7_ESM.xlsx › mutation_data

Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.

Karasaki T et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2016

Functional polymorphisms in Nrf2: implications for human disease.

Cho HY et al.

Free Radical Biology & Medicine, 2015

Diagnostic Mutation Profiling and Validation of Non-Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform.

Quinn AM et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2015

Cross-cancer profiling of molecular alterations within the human autophagy interaction network.

Lebovitz CB et al.

Autophagy, 2015

Tongue carcinoma infrequently harbor common actionable genetic alterations.

Tan DS et al.

Bmc Cancer, 2014

Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.

Okamoto I et al.

Oncotarget, 2014

24810493 (PubMed )
Supplement: oncotarget-05-2293-s001.pdf

Landscape of genomic alterations in cervical carcinomas.

Ojesina AI et al.

Nature, 2014

1–50 of 57 papers
Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."